Myriad Genetics Inc expected to post a loss of 1 cent a share - Earnings Preview

Myriad Genetics

30/07/2024 14:57

* Myriad Genetics Inc  MYGN.OQ   MYGN.O  is expected to show
a
rise in quarterly revenue when it reports  results on August 1
(estimated) for the period ending June 30 2024
    * The Salt Lake City Utah-based  company is expected to
report a
11.7% increase in revenue to $204.954 million from $183.5
million a year ago, according to the mean estimate from 13
analysts, based on LSEG data. (Sales Majority is on Total / Net
Revenue basis)
    * ​LSEG's mean analyst estimate for Myriad Genetics Inc is
for a
loss of 1 cent per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 3
"hold" and 4 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Myriad
Genetics
Inc is $28.00​, above​ its last closing price of $27.33. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.11       -0.10      -0.01     Beat    90.5
 Dec. 31 2024  0.01        0.01       0.04      Beat    214.2
 Sep. 30 2023  -0.08       -0.08      -0.03     Beat    63​
 Jun. 30 2023  -0.09       -0.08      -0.08     Met     5.9
 ​​Mar.        -0.19       -0.19      -0.21     Missed  -8.6
 31 2023                                                
 Dec. 31 2022  -0.15       -0.16      -0.12     Beat    26.5​
 Jan. 1 0001   -0.04       -0.06      -0.19     Missed  -216.7
 Jun. 30 2022  0.03        0.01       0.04      Beat    300
 This summary was machine generated July 30 at 13:57 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)